ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.401,38
-1,36%
S&P 500
5.983,25
-0,50%
US Dollar vs BRL
5,7795
0,82%
Bitcoin
93.380,59
-3,00%
Brent Oil
74,475
0,50%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. PepGen Inc (PEPG)

  7. PepGen Inc (PEPG) Notícias

PEPG

PepGen (PEPG)

PepGen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PEPG
DataHoraFonteTítuloCódigoCompanhia
24/02/202518:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PEPGPepGen Inc
24/02/202509:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
24/02/202509:30Business WirePepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
24/02/202509:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PEPGPepGen Inc
24/02/202509:00Business WirePepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1NASDAQ:PEPGPepGen Inc
29/01/202518:05Business WirePepGen Announces CONNECT Program UpdatesNASDAQ:PEPGPepGen Inc
16/12/202410:00Business WirePepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
21/11/202418:05Business WirePepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical DevelopmentNASDAQ:PEPGPepGen Inc
07/11/202410:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
07/11/202410:00Business WirePepGen Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
04/11/202410:00Business WirePepGen to Participate in Upcoming Investor ConferencesNASDAQ:PEPGPepGen Inc
08/10/202408:00Business WirePepGen Announces Presentations at the 29th Annual Congress of the World Muscle SocietyNASDAQ:PEPGPepGen Inc
19/09/202417:30Business WirePepGen Announces Christopher Ashton, PhD, to Retire from its Board of DirectorsNASDAQ:PEPGPepGen Inc
20/08/202417:05Business WirePepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & DevelopmentNASDAQ:PEPGPepGen Inc
20/08/202409:00Business WirePepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & DevelopmentNASDAQ:PEPGPepGen Inc
08/08/202409:00Business WirePepGen Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
30/07/202417:02Business WirePepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
26/07/202417:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
09/07/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PEPGPepGen Inc
02/07/202409:00Business WirePepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate CommunicationsNASDAQ:PEPGPepGen Inc
11/06/202408:00Business WirePepGen Announces Executive Team PromotionsNASDAQ:PEPGPepGen Inc
05/06/202417:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PEPGPepGen Inc
14/05/202417:02GlobeNewswire Inc.PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
13/03/202408:00GlobeNewswire Inc.PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
06/03/202418:01GlobeNewswire Inc.PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
04/03/202409:00GlobeNewswire Inc.PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
20/02/202410:00GlobeNewswire Inc.PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
07/02/202418:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PEPGPepGen Inc
07/02/202409:30GlobeNewswire Inc.PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockNASDAQ:PEPGPepGen Inc
17/01/202409:00GlobeNewswire Inc.Mary Beth DeLena Joins PepGen as General Counsel and SecretaryNASDAQ:PEPGPepGen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PEPG

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
ONCO3
Oncoclinicas Brasil Serv... ON
BOV
AZEV4
AZEVEDO PN
BOV
RCSL4
RECRUSUL PN
BOV
RNEW4
RENOVA PN
BOV
PRIO3
PETRORIO ON
BOV
PDGR3
PDG REALT ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
AZUL4
AZUL PN
BOV
FICT3
Fictor Alimentos ON
BOV
BRKM5
BRASKEM PNA
BOV
TPIS3
TRIUNFO PART ON
BOV
AZEV3
AZEVEDO ON
BOV
AZTE3
Azevedo & Travassos Ener... ON
BOV
VIVR3
VIVER ON
BOV
HBSA3
Hidrovias DO Brasil ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios